Characteristics of HIV-1–infected individuals
| Participant . | Age* . | HLA class I . | Follow-up† . | CD4 counts‡ . | Diagnosis . |
|---|---|---|---|---|---|
| NHL0118 | 36 | A2, 3; B51, 60 | 124 | < 0.19 | NHL |
| NHL0139 | 46 | A2; B8, 51 | 87 | < 0.06 | NHL |
| NHL0308 | 34 | A1; B8, 51 | 94 | 0.07 | NHL |
| NHL6006 | 41 | A2, 32; B7, 35 | 76 | 0.1 | NHL |
| NHL6118 | 25 | A2, 3: B8, 37 | 25 | 0.19 | NHL |
| PROG0232 | 35 | A1, 3; B7, 8 | 134 | 0.23 | Mycobact |
| PROG0341 | 33 | A24, 28: B8, 13 | 128 | 0.09 | PCP |
| PROG0642 | 43 | A3; B8, 70 | 39 | 0.04 | PCP |
| LTA0036 | 44 | A1, 32; B8, 44 | 95 | 0.36 | — |
| LTA0057 | 39 | A2, 19; B27, 40 | 162 | 0.34 | — |
| LTA1160 | 35 | A2; B8, 27 | 128 | 0.24 | — |
| Participant . | Age* . | HLA class I . | Follow-up† . | CD4 counts‡ . | Diagnosis . |
|---|---|---|---|---|---|
| NHL0118 | 36 | A2, 3; B51, 60 | 124 | < 0.19 | NHL |
| NHL0139 | 46 | A2; B8, 51 | 87 | < 0.06 | NHL |
| NHL0308 | 34 | A1; B8, 51 | 94 | 0.07 | NHL |
| NHL6006 | 41 | A2, 32; B7, 35 | 76 | 0.1 | NHL |
| NHL6118 | 25 | A2, 3: B8, 37 | 25 | 0.19 | NHL |
| PROG0232 | 35 | A1, 3; B7, 8 | 134 | 0.23 | Mycobact |
| PROG0341 | 33 | A24, 28: B8, 13 | 128 | 0.09 | PCP |
| PROG0642 | 43 | A3; B8, 70 | 39 | 0.04 | PCP |
| LTA0036 | 44 | A1, 32; B8, 44 | 95 | 0.36 | — |
| LTA0057 | 39 | A2, 19; B27, 40 | 162 | 0.34 | — |
| LTA1160 | 35 | A2; B8, 27 | 128 | 0.24 | — |
NHL indicates B-cell NHL; PCP, Pneumocystis cariniipneumonia; Mycobact, Mycobacterium tuberculosisextrapulmonary.
Age in years at HIV-1 seroconversion or first seropositive visit.
Seropositive follow-up, in months, from HIV-1 seroconversion or first seropositive visit until AIDS diagnosis or last time point studied.
CD4+ T-cell numbers × 1000/mL at AIDS diagnosis or last time point studied for LTAs.